Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
NEW YORK, Feb. 08, 2016 -- Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large ischemic strokes will be presented during two oral presentations at the upcoming International Stroke Conference (ISC) 2016, being held February 17-19, 2016 at the Los Angeles Convention Center in Los Angeles, California.
The two oral presentations will be conducted by principal investigators and leading neuroscience researchers at Yale University and Massachusetts General Hospital.
“We are thrilled to have this exciting data presented to a group of illustrious clinicians at the world’s largest and most prestigious medical meeting dedicated to the science and treatment of cerebrovascular disease,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “Edema is one of the most significant mortality risks associated with stroke and other acute CNS conditions. In fact, in the first week following an ischemic stroke, 78% of all deaths are attributable to edema and in hemorrhagic stroke, 93% of deaths are caused by this type of swelling. CNS edema continues to be a condition characterized by major unmet medical need. We look forward to sharing the full results of the Phase 2 trial evaluating CIRARA for reduction of the devastating consequences associated with edema after a severe stroke.”
Logistical details for the two oral presentations include:
Abstract LB6: GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: A Phase II Study Toward Preventing Edema After Ischemia
Presenting Author: Kevin N. Sheth, MD, FAHA, FCCM, FNCS, FAAN, FANA
Associate Professor of Neurology and of Neurosurgery
Division Chief, Neurocritical Care and Emergency Neurology;
Director, Neuroscience ICU;
Chief, Clinical Research, Department of Neurology;
Yale University, New Haven, CT
Session: A34 – Late-Breaking Science Oral Abstracts I
Date: Wednesday, February 17, 2016
Time: 4:06 – 4:18 pm PT
Location: Room 408
Abstract LB24: GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: Intermediate Endpoint Analysis as Proof-of-Concept
Presenting Author: W. Taylor Kimberly, MD, PhD
Associate Director, Neuroscience Intensive Care Unit;
Massachusetts General Hospital;
Assistant Professor of Neurology;
Harvard Medical School, Boston, MA
Session: Plenary Session III
Date: Friday, February 19, 2016
Time: 12:17 – 12:29 pm PT
Location: Hall K
Remedy will be available to meet with potential Phase 3 clinical sites and other interested parties at Booth # 629 in the Science and Technology (Exhibit) Hall.
The International Stroke Conference is the world’s largest medical meeting dedicated to the science and treatment of cerebrovascular disease. This 2½-day conference features more than 1,500 presentations that emphasize basic, clinical and translational sciences as they evolve toward a more complete understanding of stroke pathophysiology with the overall goal of developing more effective prevention and treatment.
ABOUT CIRARA™
CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 [email protected] Investors Lee Roth / Tram Bui, The Ruth Group 646-536-7012 / 646-536-7035 [email protected] / [email protected] Media Kirsten Thomas, The Ruth Group 508-280-6592 [email protected]
